Blood thinner trombix under Real-World review for heart rhythm disorder
NCT ID NCT06184204
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study in Algeria followed 398 adults with atrial fibrillation who were taking the blood thinner Trombix (Rivaroxaban). The goal was to see how safe and effective the drug is in everyday medical practice, and how it affects quality of life. Researchers tracked serious bleeding events and other side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rivaroxaban (brand name Trombix), a blood thinner
What this could lead to
If results are positive, this could confirm that Trombix is a safe and effective option for managing atrial fibrillation in real-world settings in Algeria.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other populations or settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOUICHE private healthcare
Constantine, Algeria
-
Ali Lahmar private healthcare
Oran, Algeria
-
BEDAI private healthcare
Annaba, Algeria
-
Berboucha
Annaba, Algeria
-
Boudjelal private healthcare
Batna City, Algeria
-
Boumaaza Private healthcare
Algiers, Algeria
-
CHU Mustapha
Algiers, Algeria
-
CHU Oran
Oran, Algeria
-
EID private healthcare
Oran, Algeria
-
EPH Tipaza
Tipasa, Algeria
-
Fernane private healthcare
Tizi Ouzou, Algeria
-
HAMDI private healthcare
Constantine, Algeria
-
KHAITER Private healthcare
Blida, Algeria
-
Mouffok private healthcare
M'Sila, Algeria
-
NASSOUR private healthcare
Tlemcen, Algeria
-
OKBI Private healthcare
Biskra, Algeria
-
Sebbagh Private Healthcare
Sidi Bel Abbes, Algeria